# Roswell Park Ovarian Cancer SPORE

> **NIH NIH P50** · ROSWELL PARK CANCER INSTITUTE CORP · 2024 · $1,745,539

## Abstract

Overall Summary – Roswell Park Ovarian Cancer SPORE
This is the revised competing renewal application of the Roswell Park Ovarian Cancer SPORE. We have made
significant progress on the translational objectives and human endpoints of each Individual Research Project
(IRP). Our highly successful Developmental Research Program (DRP) and Career Enhancement Program (CEP)
have catalyzed new translational ovarian cancer research projects, collaborations, and extramural funding for
awardees. Our overarching goal remains unchanged: to conduct multidisciplinary, mechanism-based and
collaborative translational research that will have the highest possible impact for women with ovarian cancer.
Because immunotherapies have met with only modest success in ovarian cancer patients, we continue to
uniquely focus on novel strategies for generating effective anti-tumor immunity by unraveling immune-resistance
mechanisms and identifying novel proteogenomic biomarkers of responsiveness. After significant planning and
guidance by our Internal and External Advisory Boards, and Patient Advocate Committee, we have leveraged
our highly successful DRP and CEP to propose three bi-directional translational IRPs addressing basic and
clinical research questions of importance in ovarian cancer. The new IRP1 and IRP2 evolved as a result of two
DRP awards and the new IRP3 developed from a CEP award. IRP1 will test an oncolytic virus armed with a
CXCR4 antagonist in combination with PDL1 blockade to abrogate tumor immune suppression and limit T cell
exhaustion in a randomized Phase I/II clinical trial. IRP2 will test a novel strategy of rendering NY-ESO-1-reactive
TCR transgenic T cells to be insensitive to the suppressive action of TGF and concomitantly neutralize M2-
macrophages/myeloid-derived suppressor cells. IRP3 addresses the completely novel concept of identifying
mismatch between immunopeptidomes of ovarian cancer cells versus dendritic cells and leveraging a
computational approach of bypassing such mismatch. IRP1 commences with a planned clinical trial; the Phase
I/II clinical trials in IRP2 and IRP3 will commence in year 3 following preclinical, IND-enabling translational
studies. The program also continues to expand opportunities for new avenues of ovarian cancer translational
research via its successful DRP and CEP. The four highly integrated, interconnected shared resource cores –
Administration, Biospecimen & Pathology, Biostatistics & Bioinformatics, and Immunogenomics – bring
innovative technology and resources to the SPORE and do not duplicate pre-existing shared resources available
at Roswell Park. This application is strongly supported by nearly $4M institutional commitment to ensure its
success of conducting highly innovative translational research that changes the clinical practice paradigm in
ovarian cancer.

## Key facts

- **NIH application ID:** 10897908
- **Project number:** 5P50CA159981-10
- **Recipient organization:** ROSWELL PARK CANCER INSTITUTE CORP
- **Principal Investigator:** KIRSTEN B. MOYSICH
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,745,539
- **Award type:** 5
- **Project period:** 2013-09-18 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10897908

## Citation

> US National Institutes of Health, RePORTER application 10897908, Roswell Park Ovarian Cancer SPORE (5P50CA159981-10). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10897908. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*